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[1] 
 
INTRODUCTION 
 
 
 Infection and sepsis are a major burden in management of patients with 
liver cirrhosis. Its occurrence alters the natural course, precipitates hepatic 
encephalopathy and is associated with increased risk of mortality. 
 
 Hepatic encephalopathy (HE) impairs neurological profile in patients with 
liver cirrhosis [1-4] and alters clinical outcome in these individuals. Treatment 
options include administration of intravenous antibiotics, antifoam measures like 
rifaximine, lactulose and other supportive measures.  
 
Patients with liver cirrhosis are prone for infections which culminate in 
HE. Hence this study is planned to at this aspect. 
 
 
 
 
 
 
 
  
[2] 
 
AIMS AND OBJECTIVES 
 
 To assess spectrum of infections precipitating hepatic encephalopathy in patients 
with decompensated chronic liver cirrhosis. 
 
 
 
 
 
 
 
  
[3] 
 
MATERIAL AND METHODS 
 
Source of data: 
Patients with cirrhosis admitted to PSG Hospital during the study period 
fulfilling the inclusion and exclusion criteria. 
Ethics  Committee  Permission: 
The  study  was  initiated  after  obtaining  permission  from  the  institutional  
ethics committee, PSG Institute of Medical Sciences and Research, Coimbatore. 
Study center 
The study was done in the Department of Internal Medicine and Department of 
Gastroenterology, PSG IMSR, COIMBATORE. 
Type of Study: It is a observational type of study.  
Inclusion Criteria: 
Patients of with diagnosis of liver cirrhosis and hepatic encephalopathy 
admitted in PSG hospitals were included.  
Exclusion Criteria:  
Patients with history of  Gastrointestinal bleed, Hepatocellular carcinoma were 
excluded. 
Study Period: The study included prospectively recruited patients since February 
2015 to August 2016. 
 
  
[4] 
 
Method of collection of data: 
Data was collected through a pretested proforma which included various patients 
details like age, sex, detailed past history, personal history, treatment history, 
clinical examination, diagnosis,  and  
laboratory investigations (Liver function tests, Complete blood counts,  
prothrombin time, renal functions,  serology for hepatotropic viruses, ultrasound 
abdomen and serum ammonia).  
Sepsis screening:  
Blood for total counts and pan cultures were done in all cases prior initiation of 
antibiotics. Pan cultures included blood, urine and ascitic fluid cultures. Ascetic 
fluid was sent for culture in blood culture bottles during the admission. In few 
selected individuals serum procalcitonin levels were measured. 
Measuring serum ammonia levels: 
Stasis free venous blood was collected sodium heparin containing vacutainer and 
immediately transported in ice bath within 20 minutes of sampling. During 
sampling clenching of ﬁst or application of tourniquet were avoided. This is done 
to avoid ammonia levels due to release from skeletal muscle. 
Testing for hepatic encephalopathy: 
Modiﬁed West Haven criteria were used for grading hepatic encephalopathy (HE) 
in all patients. Clinical findings and data on grades of hepatic encephalopathy 
were entered into proforma which was used for later analysis. 
 
[5] 
 
   
 
 
 
 
[6] 
 
 
 
Special tests were used for diagnosing minimal hepatic encephalopathy (MHE). 
These are shown in image above. 
 
 
 
 
 
 
  
[7] 
 
STATISTICAL METHODS 
1.  Clinical data of patients collected 
2.  Several variables have been collected and entered in the Microsoft 
excel sheet. 
3.  All analyses were done with SPS software 
4.  Value of p< 0.05 is considered as statistically significant. 
5.  Statistical analysis have been done for all variables and they were 
analyzed accordingly. 
6.  The data are reported as mean +/- SD or the median, depending on 
their distribution 
 
 
 
 
 
 
 
 
 
 
 
[8] 
 
REVIEW OF LITERATURE 
 
Hepatic encephalopathy (HE) is a umbrella term which includes range of 
neurologic and neuropsychiatric impairments in patients with significant liver 
disease [1–4].  
 
This was initially observed by Gabuzda and colleagues, who came across similar 
syndromes while treating patients with ascites. This was a landmark study  which 
illustrated role of ammonia in causing HE. The study also used resins for its 
treatment. [5,6]. 
 
Types of hepatic-encephalopathy:  
HE can be classified as 3 types as described below.  
 1st type is Type-A  that was related to that of  ALF. 
 2nd type is Type B that was related to that of  porto-systemic shunts san any kind 
of the  liver disease which is intrinsic. 
 3rd type is the Type C that was related to that of  CLF or that of the cirrhosis. 
 
 
Out of this 3 types, 3rd type that is Type C was the frequently occurring and it has 
been divided as persistent encephalopathy, and episodic encephalopathy, and also 
the minimal HE. [8] 
 Encephalopathy 423 
[9] 
 
 
 
Subtypes of Type C Hepatic encephalopathy: 
 Periodic VARIATIONS of mental condition of patients varying with that of  
severity-extent as well as time taken for the episode characterizes Episodic HE. 
Such sort of episodic events may be because of the underlying precipitating 
factors which are the causatives of hypoxic ischemic encephalopathy. or  it can 
also occur even when the obvious precipitating factors are absent, this condition is 
known as spontaneous-hepatic-encephalopathy.  
 
 Recurrent Hepatic-encephalopathy: In this condition HE occurs two times or 
greater than 2 times in a period of one year. 
  
[10] 
 
 Persistent Hepatic-encephalopathy was defined as the occurrence of the 
impairment of cognition baseline that lasts for greater than two weeks that is 
owing to the hepatic dysfunction which causes negative impression on that of 
social function as well as the function of   occupation. 
 
 
 
 
Other Types of Hepatic Encephalopathy:  
 Minimal hepatic encephalopathy (MHE) has a definition that hepatic 
encephalopathy that occurs in the patients who had hepatic disease with 
completely competent mental condition and that of CNS examination however 
these individuals will have defects of cognition in an abled neuro-psychometric 
assessment scales [2].  
 
[11] 
 
 Overt-HEPATIC-ENCEPHALOPATHY is defined as a condition of the clinical 
scenario of the Hepatic encephalopathy, that too in several ranges of neurological 
as well as mental variations as seen in the patients with that of hepatic disease. did 
 
Classifying of hepatic encephalopathy & semi quantification of the  
 Extent-of-severity of overt Hepatic Encephalopathy. 
It was done with the use of West Haven criteria [10].  
Hepatic encephalopathy holds 5 levels which were ranged from level zero to level 
IV. This is shown in next table. 
 
 
 
[12] 
 
 
 
Pathogenesis of Hepatic encephalopathy: 
  
Exact molecular basis responsible for the HE is still unknown. Possible 
mechanisms include primary gut-derived toxins. In addition along with NH3, 
Various numbers of the putative toxins is being considered as that of evidential 
mediation involved in hepatic encephalopathy [12]. 
[13] 
 
 
Another interesting issue in the Hepatic-Encephalopathy is that of absence 
of this particular clinical scenario in the individuals with that of  Porto-systemic 
shunting of the blood nevertheless in the patients who has no hepatic disease. 
However there are exceptions for that of rule where overt-HE was very less 
commonly evidenced [13]. 
 
 Implication of clearance of intestinal toxins in the prevention of HE can be 
proven by the fact that Overt HE occurs in patients with normal liver architecture 
but with lack of portal perfusion and further manipulation of splanchnic venous 
circulation, like splenorenal shunts. However, lack of portal perfusion alone is not 
significant to cause HE as the hepatic arterial flow increases and compensates for 
the portal deficit. 
 
Ammonia-NH3;  
 It has been evidenced that lot of data is available which shows that NH 3 As 
a important mediator in the process of hepatic encephalopathy. During the period 
when many other theories were developed, few if any studies showed a 
correlation between the ammonia blood level and this verity of HE. As mentioned 
previously, this particular problem was presumably due to ammonia assay 
problems prevalent at that time. In the current quoted literatureat least three 
studies show good  
Ammonia has direct neurotoxic effects in very high levels more so in patients 
with urea cycle defects [14]. Seizures and florid cerebral edema are common in 
[14] 
 
acute liver failure with urea levels (over 200mol/L) [15]. In chronic liver disease 
cerebral edema is subtle with no seizure history.  
 
Other postulated mechanisms for HE in patients with chronic liver disease 
include:  
 GABA/benzodiazepines 
 Endogenous opiates 
 Plasma amino acid imbalance/falseneurotransmitter 
 
 
 
 
 
 
  
[15] 
 
Figure : eliciting possible mechanism’s for hepatic encephalopathy 
 
 
[16] 
 
Figure : eliciting possible mechanism’s for hepatic encephalopathy 
 
 
 
 
[17] 
 
 
Precipitating factors for hepatic encephalopathy: 
 
Hepatic encephalopathy is of 2 types: spontaneous and precipitated. 
 The main precipitating factors in the development of HE in those individuals of 
CLD include: 
 Sepsis 
 Electrolyte imbalance 
 Gastrointestinal bleed 
 Renal failure 
 Excessive diuretic use 
[18] 
 
 
 
 
[19] 
 
 
 
Role of systemic sepsis:  
Infections in cirrhotic patients have often been known to precipitate bouts of overt 
HE. Encephalopathy develops in severe infections in patients having no 
underlying liver disease, which gives reasons to think that this syndrome could be 
mediated by other mechanisms [20]. Covert HE is seen to first appear after the 
elevation of acute inflammatory markers in blood.  
 
 
 
[20] 
 
The best illustration of the role of inflammatory markers in covert HE was that of 
precipitation of hyperammonemic condition with the help of per-oral glutamine 
challenge [21].  Fast degradation of the glutamine with the help of intestine 
glutaminases activity causes two to three fold increase in blood ammonia. An oral 
glutamine challenge assay with the help of specific tests of  psychometry leads to 
the revelation of an important phenomenon. This test in general do not change 
psychometry- performance in many number of patients until systemic markers of 
inflammation were elevated. The reason behind it has to be determined [22], the 
most probable being the attachment of inflammatory cells/cytokines to that of 
endothelial cells of cerebrum so that normal  exclusion effect can be enabled 
[22,23,24]. Early identification and treatment of infections is hence crucial in the 
management of HE regardless. 
 
Bacterial  infections  represents  one  of  most  common  and  important  reason  
for that of hepatic  failure as well occurrence of hepatic complications and death 
in these patients owing to cirrhotic process. 
And hepatic encephalopathy was one of the  most  important  cause  of  repeated  
hospitalizations,  increased costs of healthcare in cirrhosis  and impaired health-
related  quality  of  cirrhosis  patient. 
 Bacterial  infections  makes  a series  of altered function events of  immune  
which  develops  Subsequently   during the development   of  cirrhotic event .  
In majority of cases, infections in general were resulted from the gram –ve 
bacteria originated from the intestines, and also gram +ve  bacterial causes are the 
[21] 
 
most commonly encountered causes of the infection most commonly in the 
patients who were hospitalized.   
 
  Negative  impact  by  infections  in  cirrhosis  patients were attained by  various 
indices of prophylaxis which includes   antibiotic  usage,  early  detection  in high-
risk  group  and  management  of  infections  once  it  developed. 
 
   The method  of  prevention  of  infections with the help of diagnostic tools 
related to the processes involved in changed gut microbes as well translated 
bacterial mechanism and altered function of immunity by  investigation  on  the 
mechanisms  of  altered  gut  microflora,  translocation  of  bacteria,  and  immune 
dysfunction  which  will  lead to  development  of  most  effective  prevention  as 
well as  safer method  to  compare  which  are currently available. Investigation 
which are specific for initial clinical scenario of infection helps in appropriate 
diagnostic as well as for management of infection. [74] 
Severity and incidence of infections higher in cirrhosis patients compared 
to that of patients without cirrhosis. [75] 
Mortality rate is higher in infection with multiresistant organisms   in  
Cirrhosis then in  non-cirrhosis  patients. [75] 
 
 
[22] 
 
 Incidence of end organ damage is more in the cirrhosis patients then in  
Non-cirrhosis patients. [75] 
 Delay  in diagnosis  and  starting  treatment  results  in  higher  mortality  
in  Patients with unstable hemodynamical status. [75] 
Patients with SBP, addition of supplementary albumin to antibiotic  
treatment  reduces  mortality. [75] 
     SBP  and  UTI  are  more commonly occurs past  skin infections, 
pneumonia  , soft -tissue pathologies in cirrhosis patients. [75] 
Various factors related to increase in chances of infections were varied 
liver malfunction, reduced ascetic  proteins  concentration, variceal bleeding, 
previous spontaneous bacterial peritonitis as well as hospital stay/admission.  [75] 
CONSEQUENCES OF BACTERIAL INFECTION: 
Septicemia caused by the bacteria were the causes of decompensation of liver 
cirrhotic process in an acute phase. [76] 
Acute bacterial infection will show cirrhosis which can be compensated and 
related to new-onset hepatic as well as other organs failure. 
  
 
 
[23] 
 
 
 
 
 
ABOVE FLOW CHART SHOWING PATHOPHYSIOLOGICAL BASIS 
INVOLVED IN OF ACUTE ON CLF AND END ORGAN DYSFUNTION 
OF CIRRHOSIS CAUSED VIA INFECTION. 
  
[24] 
 
 
 
 
 
PATHOGENESIS OF BACTERIAL INFECTIONS IN CIRRHOSIS: 
 
                       
 
   
  
[25] 
 
 occurrence of bacterial infections in cirrhotic individuals  owing to various causes 
which   consists altered functions of liver, portal vein-systemic-shunt, more severe 
translocated  bacteria, cirrhotic process related altered function of immunity as 
well as genetics. 
 
Gut microbiota  
Intestinal barrier dysfunction 
Immune dysfunction 
Genetic predisposition to the bacterial infections 
 
 
 
 
 
 
 
 
 
  
[26] 
 
Mechanisms of Hepatic encephalopathy: 
 
  
[27] 
 
Diagnosis of hepatic encephalopathy: 
Variation in patient mental condition / before to performing of psychometric test 
of the individuals of suspected /  known cirrhotic patients to be regarded  due to 
HE that is until proven nevertheless.  Individuals suffering from cirrhosis which 
cannot be compensated were more inclined to  develop overt Hepatic 
encephalopathy. HIGHER STAGE liver diseases associated with other events 
which could make variations of mental condition, which has to-be identified as 
well as to be treated. Practically, HE as well as other causes along with  the  
encephalopathy which have been treated concomitantly in most of the chronic 
liver disease patients. Hypothyroidism has often also  been encountered with HE 
[27]. 
 
Underlying cirrhosis or portosystemic shunts without cirrhosis, very rarely, which 
is primary to the diagnosis or rather suspicion for HE. When encountered with 
overt HE  with a well-preserved function of liver seek for greater collaterals of 
portosystemic circulation, which is  a major  focus of septic and occult intake of 
drug activity on central nervous system active. 
 
In patients with Diabetes have been proposed that they were related with overt 
hepatic encephalopathy reported to be associated with overt HE even while it is 
being comparatively was being preserved. This was linked to motility-movement 
disorders in diabetic individuals related to bacterial overgrowth in small-intestine 
[28,29]. The clinical signs of asterixis, loss of motor activity and confusion are 
[28] 
 
found with biochemical evidence, with this neurological deterioration is 
attributable to HE.  
430 Part III: Consequences of Liver Disease 
Asterixis 
Tremor of the wrist when it is kept in dorsiflexion is called as Asterixis, it 
resembles like a bird flapping its wings. The term “Asterixis” word came from 
Greek a (not) and the sterixis (fixed-position). Which denotes failure to maintain 
actively position or posture and in 1949 it was 1st said by Adams and Foley [1]. 
This is elicited classically by dorsiflexion of hand when fingers and forearm are 
extended and series of involuntary and rapid movements, extension-flexion type 
of wrist movements, this is also known as “hepatic flap” [4]. This can elicited 
with protrusion tongue, foot dorsiflexion,  clenching of fist, and forced closure of 
eyes. This is due to supra-spinal motor centers and abnormal function in its 
pathophysiology. This can be seen classically in grade 2 hepatic encephalopathy 
in West-Haven-scale. However, this type of encephalopathy symptoms also seen 
in some other system failures and imbalance in electrolytes. 
 
Other neurologic findings 
Hyperreflexia, hypertonia, transient decerebrate posturing and extensor plantar 
reflexia may occur. This signs are classified into three categories: coordination 
and motor abnormalities, dementia, and progressive signs of cerebral-dysfunction, 
and signs which  are also occur in metabolic-encephalopathy. The most common 
abnormality in these patients is the disruption of smooth-pursuit eye movement (S 
P E M) [30]. When patient had this sign in one episode of hepatic encephalopathy 
[29] 
 
while stay in all its remission [31]. Signs like asterixis, hyperreflexia, nystagmus, 
ataxic to finger-nose, ataxic to heel-shin, and dysdiadakokinesia. 
 
 
 
 
 
  
[30] 
 
Scales to assessment of overt-HE in Clinicals:  
These include the following: 
 West Haven criteria 
 HESA (hepatic encephalopathy scoring algorithm) 
 CHESS (clinical hepatic encephalopathystaging scale) 
 
 
 
 
 
 
[31] 
 
Laboratory diagnosis 
Laboratory investigations which gives an limited value for diagnosing HE, 
specially for a hepatic cirrhosis patient with previous episodes of overt HE who 
are presenting to hospital in altered mental-status. These investigations will helps 
ruling out the causes of hepatic-encephalopathy, other precipitating causes of HE. 
[32] 
 
 
[33] 
 
 
 
[34] 
 
 
 
  
[35] 
 
Blood serum ammonia: 
Impaired mental-status in liver failure patients should be considered and start 
treating like hepatic encephalopathy which is unless proven as other. So blood 
serum-ammonia is not routinely recommended in diagnosing of hepatic-
encephalopathy. It will help in some rare circumstances but now it limited 
predominantly to using in a research settings.  Some studies showed a strong 
correlation between arterial and venous ammonia levels [7].  
 
Cerebrospinal fluid amino acids 
When the concentration of  ammonia increases in brain, which releases glutamate 
from cellular stores which is converted into glutamine, in astrocyte cells. 
Aminoacid is released in large quantities into cerebro-spinal fluid (CSF) which 
causes increase in its concentrations. So many postmortem human and 
experimental studies reports showed minimum of 2-fold increase in the glutamine 
levels in CSF of the hepatic encephalopathy patient with HE [33]. Phenylalanine 
and tyrosine are the other amino acids which increase in great amounts in HE[34]. 
This biogenic-amines act as agents to nor epinephrine and dopamine, which  can 
alter the mono-aminergic acion in the brain. The significant rise in levels of amino 
acid will also cause same level of neurologic deterioration which is demonstrated 
by levels of  CSF alanine. 
 
This predicted to arise from metabolism of glutamine, this is incorporated into 
Krebs-cycle. These investigations are presently involved in studies and research 
which will take long time before it is clinically applicable. Individuals with 
[36] 
 
hepatic-encephalopathy will most commonly have coagulopathies, hence lumbar-
puncture performed only if it is absolutely indicated. 
 
Psychometric-tests: 
Minimal hepatic-encephalopathy was the neurocognition disorder where 
individual has an mal-performance in various psychometric tests. This usually 
occurs in cirrhotic individuals how ever it can be observed in initial stages of 
fibrotic process as well as portosystemic shunting. This entity, recognized during 
1970s, were originally called as sub-clinical HE which was relied on the 
performance of individuals in trail-making as well as various cognitive test 
[32,35]. A study was conducted by Hamster et al to understand the several  neuro-
cognitive domains altered in this condition. [36]. He conducted greater than three 
hindered various test of psychometry to estimate cognition domain which is 
varying from premorbid-intelligence levels and verbal-abilities to visuomotor-
function and  its coordinatents.  
 
With the help of statistic analysis of discrimination it has been found that 
line-tracing test, peg-board, aiming-steadiness motor performance-scale, and digit 
symbol test can potentially helpful in differentiation of cirrhosis and non-cirrhosis 
individuals. These were initial efforts that resulted in standardization in testing 
methods that is currently known as minimal HE.  
. 
 
 
[37] 
 
Paper & pencil tests 
 
PHES-Psychometric Hepatic-Encephalopathy-Score) 
 Test battery has been devised byWeissenborn and Schomerus et al. which 
depends upon the results of Hamster study [15]. PHES constitutes these tests:  
number-connection-test-A (NCT-A), number-connection-test-B (NCT-B), digit-
symbol-test (DST), line-tracing-test i.e,LTT, and serial dotting test i.e,SDT. Test-
battery has been advocated on higher number of volunteer individuals in germany 
who are in good health that is to collect normal data which is according to aged 
wise & has been further assessed by testing on that of individuals with non-
alcoholic cirrhosis. Such testing domains are motor speed, d accuracy as well as 
visual-perception, visuo-spatial-orientation, visual-construction, concentration, & 
to a smaller amount of extent memory. Many articles has proven that age & 
education has an influence seen-on tests such as NCT-A as well as NCT-B [37]. 
Test-battery primarily had utmost attention in Italy, Spain, and Mexico, and Great 
Britain has been attained local normative information. Scarce info availability as 
well as copyrighted issues, that too with problems evidenced in applying as well 
as giving score to the test, has its attention in US [38]. 
 
RBANS (Repeatable-Battery-for-Assessment-of –Neuropsychological-Status) 
It was the established-battery for that of assessment of dementia as well as for 
various  neurocognitive disorders [39]. This was a paper and pencil test which has  
4 alternative forms (A, and, andC, and D) and it lasts for almost twenty to thirty 
minutes for administrating. This have extensive normative databases throughout 
[38] 
 
that of ages twenty to eighty nine years in US [37]. Initial reports which were 
applied on individuals who have been on wait for hepatic transplantation has 
shown a close correlation b/w model for end stage liver-disease (MELD) score 
and its-performance in that of RBANS [40]. The main drawback associated with it 
was that of appreciable learning effect showed in the individuals who were tested 
at close timings, which will limit its usage with assessment of response for 
therapy. 
 
Computerized-psychometric-tests 
In the past some years several computerized test-batteries has been advocated for 
diagnosis of minimal Hepatic-Encephalopathy [38]. Such testing systems aimed at 
intervening in few problems which were important that were observed with that of 
paper & pencil test which consists available-issues, concerned principles about 
administration of the test, as well as-scoring. 
                                  
  Many computerized testing’s were able to generate aged matching result 
at the termination of the test period. Such tests were seen in internet and it could 
be in usage-free-of-charge or for a basic fee. It also offers convenient of abled for 
administration in the op settings. Most popular testing-systems were inhibitory-
control-test (ICT) as well as cognitive-drug-research (CDR) -test. 
  
[39] 
 
Inhibitory-control-test 
It was an organized test used in main purpose in determination of deficits 
in attentiveness as well as responsive inhibitedness in that of individuals of 
ADHD attention-deficit-disorder, schizophreniaC as well as  traumatic-brain-
injury. In Bajaj et al study, it was found that test as well as the subject has been 
showed in various letters at five hundred ms sessions on the screen of laptop. The 
individual has been enquired to put attention at the  X and Ys which were 
interlayed in-between those words. These people were asked for response that is 
by typing  space bar that is at the time  X was followed by Y /or Y was followed 
by X, which was the “target,” and for refraining  from that of response when X 
was followed by X or Y was followed by that of Y, which was the “lure.” The 
individual  have to go via  6 runs of two minutes for every time that too with 
addition for trained run in the beginning. These were graded basing upon  
lureresponse, as well as greater than 5 lures diagnosed as that of minimal hepatic 
encephalopathy with eighty eight percent sensitivity. In US, such tests were being 
in investigation chiefly and has been applied by a 1 investigator.Dr.Bajaj, in 2 
centers  Wisconsin & Virginia [43]. Neverthless, this was  not  being performed 
appropriately in countries like  Europe, which makes it least popular in different 
part of Atlantic [44]. 
 
  
[40] 
 
Cognitive-drug-research-test 
CDRT testing system is validated in diagnosing of the minimal-HE  with the help 
of investigators from  Newcastle, [45]. The CDR-test was presented on the  
computer-screen that too as  patients responded to the “Yes/no” response-box. 
This battery was consisted with 7 various tests. These scores were demonstrated 
on the scale-of-performance in 5 various-domains, that consists power-of-
attraction, and continuity of attention, and quality of episodic memory, and quality 
of-working-memory, and speed-of-memory. Nevertheless , 1 limitation in this 
testing is the patients has to be undergone practicing  sessions of one to seven 
days that is before the date of testing that is for familiarity. 
 
Critical-flicker-fusion-frequency-test 
It was designed by Kerchiefs etal. In year-2002 that is helpful in the diagnosing of 
minimal-HE, it was currently a well-organized neuro-physiologic-test basing with 
the principle of hepatic-retinopathy [46]. Muller-cells of the retina (which are glial 
cells) we been proposed to have the same changes as that of  the brain-astrocytes . 
This has been considered to cause variation in the perception in light frequency as 
received by the retina. This test has shown a patient light-pulses, beginning with 
greater frequencies of 60 Hertz, which will reduce in a progressive manner by 0.1 
Hertz/second. With this higher frequencies the individual perceived these as a solo 
stream of light, however the critical-frequency was when individuals initially 
receive it as the discrete light-pulses. Critical-frequency of less than 39Hertz 
diagnosed as  minimal-HE that too of higher sensitivity as well as that of 
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specificity, and it usually coorganised with  paper-and-pencil psychometric tests. 
These tests could  been administer  in ip as well as op setting and it lasts for about 
fifteen minutes as a whole. 
Binocular-vision was a preimportant tool in case of  optimal performing  in the 
test. This  was not affected by education/occupation and it was just merely related 
to age. This  was majorily applied in that of  therapy trials in individuals with 
HEi.e,hepatic-encephalopathy due to the capability of demonstration of improving 
that too with no learning-effect [47,48,49].  There is very scarce information 
available in US , it was the major reason which makes it  low popular 
 
Electro-encephalo-gram 
Electroencephalograms (EEG) is useful in studying neuro-physiologic state of 
individuals who had  cirrhosis [50,51,52]. This was in general applied in that of 
research as well as that of  clinical setting. In the Earlier one , it has been in  use 
for  following: To assess  effects of therapy  (dietary /pharmacologic), porto-
systemic shunt insertion,or surgery or hepatic transplantation. For quantifying the 
status of the physiological variations in brain and also to assess its association 
with that of several tests which were applied in diagnosing minimal-Hepatic-
encepahlopathy.It was the common used diagnosis  tool with diagnosis of  
cirrhosis patients  those with bad consciousness. 
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 Various findings on EEG in general were: 
_ Generalized slowness of  background ElectroEncephaloGram activity, that was  
objectively quantifiable but could be observed  in that of various metabolic-
encephalopathies. 
_ Reduced amplitude  waves. 
_ Occurrence  of triphasic waves as well as the  bursts of slow-activity of theta as 
well as delta range. 
 
Brain-imaging:  
Increasing in the past  decades, cerebral edema was characterised by several types 
of magnetic-resonance-imaging I,e MRI techniques of  brain [16]. This was 
majorily observed in white matter-brain and all grades of HE. A computerized 
tomographic- CT scan of the brain was performed routinely with the  patients with 
changed mental condition, that too to find  the absence of concomitant etiologies 
such as  intracranial-hemorrhage as well as space-occupying-lesions. 
Treatment: 
*The present standard of treatment  of  overt hepatic encephalopathy comprises 4 
important  plans : 
(i)  Supporting care for the individual who had altered mentation; 
(ii)  Concurrent etiological factor of hepatic encephalopathy are searched and 
managed when possible; 
 (iii)  Stimulating causes were identified and are corrected promptly; and  
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(iv)  Empirical therapy in Hepatic encephalopathy till current times, lactulose 
has been approved management tool for HE in the US. Currently lactulose, 
along with rifaxmin, which is been used long time only being accepted 
treatment in the US, is available for managing some types of individuals 
with recurrent episodes of HE [53]. 
 
Supportive care 
*NG tube which can deliver large quantities of lactulose  is  commonly used as 
treatment modality for HE [11]. Aspiration is hence a consequential risk in 
patients of intensive care units. Elective intubation is preferred individuals of high 
grade HE (e.g., stage 3 or 4, by WestHaven-scale), is well justified only if severe 
upper GI bleeding has been a factor. Supplementation of nutrients for patients 
who are not conscioust. Generally  nutrition supplement is limited for initial days 
in inpatient care owing to frequency of investigations as well as the necessity of 
lavage measures of intestine to remove blood. 
 
Some more etiological factors - encephalopathy 
*The 2nd strategy is to find out the what are other factors causing encephalopathy 
in unconscious patients with overt HE as the diagnosis of  HE is made only in the 
absence of other causes of encephalopathy. In case of co-existence of the other 
causes, they have to be diagnosed and treated. Care should be taken to avoid 
induction of complications due to lactulose dosing like dehydration and 
hypomagnesemia. 
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Precipitating factors 
The 3rd strategies which are employed in management in recurrent episodes of 
significant HE which is very important. In patients with advanced hepatic 
cirrhosis (Child–Pugh=class C) recurrent episodes of minimal or significant HE  
are precipitated are defined factors. Identification and the correction of the prompt 
factors is very effective therapy in treatment of HE. The recovery rates of HE is 
with correction of factors which precipitate alone has been reported as 80–
90%[54]. Because of the overlap (e.g., lactulose is also used in to clear GI bleed) 
sometimes it is so difficult in find out what is actually  reversed the episode of 
HE. Further matters which are complicating and many cirrhosis patients who have 
2 are more than 2 simultaneous precipitating factors for hepatic encephalopathy. 
When studies like randomized controlled trials conducted this type of issues made 
it very difficult in treating of minimal or significant HE. Multiple precipitating 
factors and added concomitant causes of hepatic encephalopathy together will 
cause difficulty in conducting the “controlled trial”. The events, seeking for 
factors and treatment of precipitating factors is very important and effective 
treatment of minimal and significant hepatic encephalopathy. Especially in 
patients with large spontaneous/surgically created portosystemic shunt which tend 
to have more episodes of spontaneous encephalopathy [55].  
Some of the additional comments which are warranted on precipitating 
factors of hepatic encephalopathy. Sepsis is to be the most likely dominant factor 
of HE. In many cases identifying and treating of major focus of the infection is 
not successfully in many cases, recovery from episodes of the HE can be very 
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much protracted or  patient who may have tendency of recurrent episodes of 
significant hepatic encephalopathy[56]. Patients  with cirrhosis may have 
tendency to develop HE in severe forms, then sepsis will be the first suspecting 
factor. The basic and important issue with sepsis is that in can induce or capable 
of causing encephalopathy by its own [20]. In difficulties of managing of  HE this 
is one more example, upper GI bleeding is also a frequent cause and  precipitating  
factor of recurrent episodes of  hepatic encephalopathy. Large undue amounts of  
ammonia is produced by digested blood in gut which precipitates the HE. In 
addition to this absence of essential aminoacid isoleucine fromed in hemoglobin 
make it still more ammoniogenic than other types of protein [19, 57]. Periodic 
catharsis and gut lavage is insisted to clear blood in gut and empirically one will 
see patient recovering from symptoms of significant HE with this type of 
therapys. Because the laxative effect of lactulose it is very difficult in knowing 
whether its unique action or purgative effect is resulting is responsible in the 
recovery of bouts of HE. Regardless, gut cleansing has been the definitive 
treatment. In conditions when the constipation/ or ileus is noted, removing blood 
out of gut could not be attained unless motility of intestine is being better. 
 It has been suggested GI motility has been decreased by HE itself, 
neverthles producing the self continuing mechanism in episode of hepatic 
encephalopathy. In conditions of constipating patients , intestinal obstruction, 
ileus, per-rectal lactulose is proved to be effective for in management of overt 
hepatic encephalopathy [58]. Low sodium levels as per number of studies have 
been reported that it has potential to clearly increase the chance of occurrence of 
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hepatic encephalopathy [59].  Hyponatremic condition also results in aggravation 
of cerebral edema which exists previously in individuals of high grade cirrhosis 
[26]. 
 
Drug therapy 
LACTULOSE 
                  Lactulose is a non-absorbed disaccharide  which used in treatment of 
HE [10,60]. In 1977 United States Food and  drug administration made  use of 
Lactulose used exclusively for treatment in hepatic encephalopathy. Data shows, 
lactulose use is superior to the use of placebo in treatment of minimal or covert  
HE [61,62,63]. 
                  Lack of data in support on lactulose in treatment of significant HE 
which is related to mechanism of  actions of this type of drugs. The data which is 
generated on based on lactulose in treating minimal HE it has efficacy in 
treatment of HE [63]. 
                 Lactulose is used widely in treatment of decompensated chronic liver 
disease patients with  minimal and significant hepatic encephalopathy.    
Rifaximin 
Rifaximin is a broad spectrum antibiotic which is minimally absorbed. 
Rifaximin is used in many trials in Europe previously[64,65,66,67]. There was no 
control-placebo   study trial was performed. When compared with veriety of 
similar agents Rifaximin (lactitol, lactulose, and some other types of antibiotics) 
which displayed consistently the same type of efficacy [66,67]. The recent study 
trial in united states of America on rifaxmin in which data provided clearly 
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indicates rifaximin decreases episodes of HE in patients who at high risk with 
these hepatic encephalopathy events (reduction upto 58%)[53]. Rifaximin is 
thought to reduce the duration of HE. There is no indication for its use except in 
prolonged overt HE. 
 
Other types of  treatment 
Since 1950 Neomycin which is been used for treatment of hepatic 
encephalopathy [68]. Same as other types of treatment for hepatic encephalopathy 
there is no evidence of abundance in supporting the efficacy of neomycin 
*A the study trial conducted in Brazil by colleagues and strauss which essentially 
proved neomycin which is no more effective [54]. Another mechanism of action 
of Neomycin has another type of mechanism of action which inhibits the 
glutaminase enzyme which is important in formation of ammonia in blood in large 
amount  results in improvement in the condition of  hepatic encephalopathy 
patients. 
 
 Other type of  Antibiotics which reverse hepatic encephalopathy:  
*Metronidazole [69], vancomycin [70], paramomycin[71], and few other 
antibiotics have been reported to reverse HE [65]. The probable mechanism of 
action is in the suppression of bacterial overgrowth. Redution of intestinal motility 
might be helpful. The advantage of Rifximin in cirrhotic patients for bacterial 
overgrowth is the sparing of bacterial flora. As the drug is solubilized by bile 
salts,it becomes less active once bile salts are absorbed into the small bowel 
resulting in the lack of effect over the bacterial flora. 
[48] 
 
The use of prokinetics and selected delivery antibiotics might be considered in 
future for the therapy of HE. 
 
Other therapies 
Immunization by urease [71], resection of colon or bypassing [72], portal 
vein stump  arterialization [73] are some treatment methods under study. Using of 
Endogenous benzodiazepines  in patients with no prior exposure to the drug 
resulted in awakening from coma by about 30 % with Flumazenil. 
 
Liver transplantation: 
When medical treatment fails, then organ transplantation may require. This 
organ  transplantation which is not performed usually due to many causes such as 
infection, organ availability, cost. It may also due changes hepatic encephalopathy 
grades in frequent admissions. The preference and priority for earlier organ 
transplantation for cirrhosis patients before episodes of hepatic encephalopathy 
which may occur can  improve in patients  neurological status and outcomes 
[17,18,40]. 
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RESULTS 
 
In this study, out of 50 patients, males were 44 (88%) and females were 6             
(12 %) 
Table 1: Sex wise distribution 
Sex Number Percentage 
Male 44 88% 
Female 06 12% 
Total 50 100% 
 
In this study, Males are more in number compared to females.  
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Figure: Sex wise distribution 
 
Females were 12 % and males were 88 %. 
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Table 2: Age wise distribution 
 
Age groups (years) Number Percentage 
<50 22 44% 
50-60 19 38% 
61-70 07 14% 
>70 02 4% 
Total 50 100% 
Mean age = 52.54±10.03 years 
 
In this study, 22 patients (44 %) were in the age group less than 50 years. 
19 patients (38 %) were in the age group of 50 – 60 years. 
 7 patients (14%) were in the age group of 61 -70 years. 
 2 patients (4%) were in the age group of greater than 70 years.    
Mean age of this study is 52.54±10.03 years 
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Figure: Age wise distribution 
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Table 3 : Etiology of Liver cirrhosis: 
 
Etiological Disease No of Patients  
Hepatitis B 3 
Hepatitis C 3 
Etthanol 35 
NAFLD 4 
Autoimmune  Hepatitis 1 
Wilsons 1 
Etiology not certain n 3 
Total 50 
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Out of 50 subjects in the study, alcohol was the etiological factor in 35 patients 
(70%) 4 patients (8%) have NAFLD as the cause , 3 patients each has  Hepatitis 
B. Hepatitis C as the etiological cause 1 each has etiological cause of 
Autoimmune hepatitis (2% ), Wilsons disease (2%), and cause was not known in 
3 cases (6%). 
   The most common etiology for liver cirrhosis in the present study was alcohol 
followed by NAFLD , Hepatitis C and Hepatitis B infection. 1 had autoimmune 
mediated liver disease and 1 had wilsons disease.  
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Figure  showing etiology of liver cirrhosis in the present study. 
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Table 4 : Infections precipitating Hepatic encephalopathy in DCLD 
Infections precipitating 
Hepatic encephalopathy Frequency* Percentage* 
Septicemia 15 30% 
Urinary Tract Infection 20 40% 
Spontaneous Bacterial 
Peritonitis (SBP) 05 10% 
Respiratory Tract Infection 07 14% 
Cellulites 03 06% 
Total 50 100% 
 
Out of 50 patients in the study, Septicemia is the infection precipitating Hepatic 
encephalopathy in DCLD in 15 patients (30 %). 20 patients (40%) had Urinary 
tract infection as the precipitating factor. 5 patients (10 %) had spontaneous 
bacterial peritonitis as the precipitating factor 7 patients (14%) had respiratory 
tract infection as the precipitating factor 3 patients (6%) found to have cellulites 
as the precipitating factor. 
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Figure: Infections precipitating Hepatic encephalopathy in DCLD 
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Table 5 
 Mean Standard Deviation (SD) 
Patient age 52.54 10.03 
Total count 13676 8581.103 
Platelet count 109000 103576.7 
Bilirubin 10.246 8.13 
PT/INR 10.68 1.70 
MELD score 26.22 8.77 
 
In this study among 50 patients, in terms of investigations: 
Mean platelet count found to be 13676,   
Mean bilirubin value noted in these patients found to be 10.25.  
Mean MELD score found to be 26.22 among these patients.   
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Table 6: Septicemia precipitating Hepatic encephalopathy in DCLD 
Infection Frequency Percentage 
Septicemia 15 30% 
 
Out of 50 patients in the study, Septicemia found in 15 patients (30%). 
Table  6: Causative agents for Septicemia 
Causative agents for Septicemia Frequency Percentage 
E.coli 07 46.7% 
Klebsiella 03 20.3% 
Enterococcus 01 6.6% 
Staphylococcus 01 6.6% 
Streptococcus agalactiae 01 6.6% 
Pseudomonas aeruginosa 01 6.6% 
Myroides 01 6.6% 
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Out of 30 patients with septicaemia  in the study, E.coli found in  In terms of 
causative agents of septicemia, out of 15 patients who showed blood culture 
proven sepsis, 
7 patients (46.6%) had  E.coli sepsis, 3 patients (20 %) had klebsiella sepsis,  1 
(6.6 %) patient had enterococcus sepsis, 1  patient each had staphylococcal (6.6 
%),  pseudomonas sespsis (6.6 % ) , myroides sepsis  (6.6 %). 
In terms of urosepsis, out of the causative agents for urinary tract infection  are 
E.coli 09 (45%),klebsiella 05(25%),enterococcus 03(15%),staphylococcus 
02(10%) and candida albicans 02 (10%). 
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Figure: Causative agents for Septicaemia 
 
 
Table 7 : UTI precipitating Hepatic encephalopathy in DCLD 
Infection Frequency Percentage 
Urinary Tract Infection 20 40% 
 
Out of 50 patients, 20  (40 % )  had Urinary tract infection as precipitating factor. 
 
  
0.00%5.00%10.00%15.00%20.00%25.00%30.00%35.00%40.00%45.00%50.00%
E.coli
Klebsiella
Enterococcus
Staphylococcus
Streptococcus agalactiae
Pseudomonas aeruginosa
Myroides
46.60%
26.70%
15%
13.30%
6.70%
6.70%
6.70%
[63] 
 
Table 8: Causative agents for Urinary Tract Infection 
Causative agents for UTI Frequency Percentage 
E.coli 09 45% 
Klebsiella 04 20% 
Enterococcus 03 15% 
Staphylococcus 02 10% 
Candida albicans 02 10% 
 
In terms of urosepsis, out of the causative agents for urinary tract infection 9  are 
E.coli (45%), 
Klebsiella in  05(25%), enterococcus  in03(15%), staphylococcus in  02(10%) and 
candida albicans  in 02 (10%). 
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Figure: Causative agents for Urinary Tract Infection 
 
 
 
Table 9 : Spontaneous Bacterial Peritonitis (SBP) precipitating Hepatic 
encephalopathy in DCLD 
Infection Frequency Percentage 
Spontaneous Bacterial 
Peritonitis (SBP) 
05 10% 
 
Out of 50 patients, 5 had spontaneous bacterial peritonitis as precipitating factor 
of HE in DCLD. 
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Table 10: Causative agents for Spontaneous Bacterial Peritonitis (SBP) 
Causative agents for 
Spontaneous Bacterial 
Peritonitis (SBP) 
Frequency Percentage 
E.coli 03 60% 
Klebsiella 01 20% 
Sphingomonas paucimobillis 01 20% 
 
Out of  5 cases with spontaneous bacterial peritonitis, 3 (60%) had E.coli sepsis. 1 
patient (20 % )  had Klesiella sepsis, 1 patient had sphingomonas paucimobilis 
(20%). 
 
 
 
 
  
[66] 
 
Figure: Causative agents for Spontaneous Bacterial Peritonitis (SBP) 
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Table 11: Respiratory Tract Infection (RTI) precipitating Hepatic 
encephalopathy in DCLD 
Infection Frequency Percentage 
Respiratory Tract Infection 07 14% 
 
Out of 50 patients, 7 had respiratory tract infection as precipitating factor of 
hepatic encephalopathy. 
 
Table 12: Causative agents for Respiratory Tract Infection 
Causative agents for RTI Frequency Percentage 
Klebsiella 04 57.1% 
Candida species 01 14.3% 
E.coli 01 14.3% 
Staphylococcus 01 14.3% 
 
The causative agents for respitarory tract infection are klebsiella 04 (57 %),  
candida species  seen in 01 (14.3 %) ,  ,E.coli  seen in 01 (14.3%)  and 
staphylococcus seen in  01 (14.3%). 
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Figure: Causative agents for Respiratory Tract Infection 
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Table 13 :Cellulitis precipitating hepatic encephalopathy: 
3 of 50 individuals had skin infections – cellulites as a precipitating factor for 
hepatic encephalopathy. 
 Table below illustrates frequency of patients with cellulites in the present study. 
Infection Frequency Percentage 
Cellulites 03 6% 
 
Table 14 showing causative agents for cellulites: 
Causative agents for 
cellulites 
Frequency Percentage 
Streptococcus pyogenes 01 33.33% 
Staphylococcus aureus 01 33.33% 
Pseudomonas aeruginosa 01 33.33% 
 
Out of 3 individuals, the causative agents for cellulites  were  streptococcus 
pyogenes in 01(33.33%), staphylococcus  aureus seen in 01(33.33%), 
pseudomonas aeruginosa seen in 01(33.33% ) . 
 
 
 
  
[70] 
 
Figure: Causative agents for Cellulitis 
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Table 15: Distribution according to Gram positivity 
Gram stain Number Percentage 
Gram Positive 14 28% 
Gram Negative 36 72% 
 
Out of 50 patients, 14 patients (28 %)  had gram positive infections,  
36 patients (72% )   had gram negative infections. 
 
Figure: Distribution according to Gram positivity 
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DISCUSSION 
 
In our study , out of total 128 patients with decompensated chronic liver disease 
with hepatic encephalopathy studied, 50 patients who met criteria of culture 
proven sepsis were enrolled . 
In our study  44(88%) were males , 06 (12%) were females. This finding of male 
preponderance is consistent with other studies .  
Study done by Franca A etal. showed male : female ratio 69:31.Study done by 
Mattos etal. finds 71.2 % males. Study done by Wyke RJ ETAL. showed male : 
female ratio of 70:30. 
Out of 50 patients in our study, 22 patients (44%) were less than 50 years , 19 
(38%) were in the age group of 50 to 60 years , 7 patients (14%) were in the age 
group of 60 to 70 years, 02 patients  (4%) were in the age group of 70 to 80 years. 
Mean age  of the patients is  52.54±10.03 years 
Among 50 patients studied , More number of patients were in the age group of 
less than 50 years (44% ) followed by patients in age group of 50 to 60 years .This 
finding is consistent with studies done by Wyke R.J etal, Mattos etal.  
T.S. Ferreira etal. study showed mean age of 52.89 years. FrancaA etal. study 
showed mean age of 45 years. 
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  In terms of etiological factors of cirrhosis of liver, out of 50 patients, 35 (70 %) 
were found to  have ethanol consumption, 4 patients (8%) were found to have 
NAFLD, 3 (6%) were found to have Hepatitis B, 3 (6%) were found to have 
Hepatitis C , 1 (2%) had were autoimmune hepatitis, 1 (2% ) were Wilson’s, and 3 
(6%) were found to have no obvious cause.  In our study ,Ethanol consumption is 
found to be most common etiological factor of cirrhosis followed by non alcoholic 
fatty liver disease (NAFLD) and others. 
This study finding is consistent with Mattos etal. study which showed alcohol 
consumption is most common etiological factor of about 35.4 %. Study by Franca 
A etal. showed alcohol consumption as most frequent cause in about 42 % of 
patients. 
In terms of culture proven sepsis, out of  50 patients in the study, 20 patients (40 
%) had urosepsis, 15 patients (30 %) had blood culture proven sepsis, 5 patients 
(10%) had ascitic fluid culture proven sepsis i.e spontaneous bacterial peritonitis , 
7 patients (14%) with endo-tracheal aspirate culture proven sepsis ie respiratory 
tract infection, 3 patients (6 % ) with cellulitis . 
This study showed highest number of patients with urinary tract infection 
followed by septicemia, respiratory tract infection and spontaneous bacterial 
peritonitis. 
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In our study , out of 50 patients, With the pan culture of blood, urine  and ascitic 
fluid cultures  , it was found that the most frequent infection was urosepsis in 40% 
followed by blood culture proven sepsis, endotracheal aspirate culture sepsis and 
ascitic fluid culture sepsis. 
In terms of causative agents of septicemia, out of 15 patients who showed blood 
culture proven sepsis, 7 patients (46.6%) had  E.coli sepsis, 3 patients (20 %) had 
klebsiella sepsis, , 1 (6.6 %) patients had enterococcus sepsis, 1  patient each had 
staphylococcal sepsis (6.6 %),  pseudomonas sespsis (6.6 % ) , myroides sepsis  
(6.6 %). 
In terms of urosepsis, out of the causative agents for urinary tract infection  are 
E.coli 09 (45%),klebsiella 05(25%),enterococcus 03(15%),staphylococcus 
02(10%) and candida albicans 02 (10%). 
The causative agents for respitarory tract infection are klebsiella 04 (57 %), 
candida species 01 (14.3 %),E.coli 01 (14.3%)  and staphylococcus 01 (14.3%).  
The causative agents for spontaneous bacterial peritonitis are E.coli 03 (60%), 
klebsiella 01(20%), and sphingomonas paucimobilis 01 (20%). 
The causative agents for cellulitis  streptococcus pyogens 01(33.33%), 
staphylococcus  aureus 01(33.33%),pseudomonas aeruginosa 01(33.33%) . 
Out of 50 patients in our study,  20 patients (40%) were found to have E.coli 
sepsis , 13 patients  (26% ) had Klebsiella sepsis, 5 patients (10 %)  had 
[75] 
 
Staphylococcal sepsis , 4 patients had Enterococcus sepsis, 3 patients (6%) had 
candida albicans sepsis. 
In our study, E.coli found to be most frequent organism causing infection 
followed by Klebsiella . 
Study done by Franca A etal. reported E.coli as the frequent organism causing 
infection in about 60 % cases 
Study  done by Qiu- ming wang etal. showed pneumococcal and E.coli were the 
common bacterial causes , Where as study done by Wyke RJ etal. reported 66.36 
% cases were Streptococcal,Staphylococcus aureus, E.fecalis , S.epidermidis as 
the causes.  E.coli found in 19.63 % cases. Klebsiella pneumonia in 12.15 % 
cases. 
In this study, Out of 50 patients, gram negative infections were found in 38 
patients (76%) and gram positive infections in 12 patients (24%)   . 
In this study , it is found that gram negative infections were more common . This 
finding is more consistent with other studies.  Study done by WR caly etal. 
reported gram negative infection reported in 72.34 % patients. 
Study done by Intekhab Ala metal. showed gram negative infection is most 
common . 
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In our study , out of 50 patients on follow up, 6 patients died. Mortality rate found 
to be 12 % of study population. 
In our study, mortality rate is in consistent with studies done by Mattos etal, 
FrancaA etal where mortality found to be 8.9 % and 12%. 
Where as mortality is high other studies such as done by Edna strauss etal, WR 
caly etal, Qiu-ming wang etal.. Mortalirty was 46.47% in study done by Edna 
strauss etal.  Mortality was 30% in the study done by WR caly etal.  In the study 
done T.S.Ferreira etal, mortality was reported as 29%. 
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CONCLUSION 
1.  In this study ,It is found that  patients with hepatic encephalopathy associated 
with  infections as the precipitating factor . 
2. In this study, it is found that urinary tract infection is the most common among 
several infections associated with hepatic encephalopathy. 
3. It is found that E.coli is the major etiological organism precipitating infection in 
this study. 
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RECOMMENDATIONS 
Hepatic encephalopathy is a major cause of morbidity and mortality. They are 
associated with many infections which will worsen the clinical condition of 
patient. These infections also play a major role in mortality, length of hospital stay 
and financial burden to the family. Thus patients with hepatic encephalopathy 
require special care and management facilities as they are more commonly 
associated with  Infections. 
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CASE SHEET PROFORMA 
Age : 
Sex: 
Ip no: 
Total count: 
Platelet count: 
Diagnosis: 
Cultures: 
CHILD and MELD score: 
Organism: 
 
 
 
 
 
 
 
 
 
 
 
ABBREVIATIONS 
HE hepatic encephalopathy 
SBP Spontaneous bacterial peritonitis  
CFF critical flicker frequency  
CHESS clinical hepatic encephalopathy staging scale  
GABA g-aminobutyric acid HE hepatic encephalopathy  
HESA hepatic encephalopathy scaling algorithm  
MARS molecular adsorbents recirculating system  
MELD model for end-stage liver disease  
MMSE mini-mental state examination  
PHES psychometric hepatic encephalopathy score 
ALF Acute Liver Failure  
CLF – Chronic Liver Failure 
 
 
 
 
 
 
 
S.No sex Sl.No age meld child PT INR BILLIRUBIN PALTELET TC HE GRADE IP NO DCLD & INFECTION ORGANISM
1 F 1 60 16 C 22.5 2.06 11.6 96000 3700 1 I15000085 AUTO IMMUNE STATUS SEPTICEMIA,SBP ECOLI
2 M 2 62 31 C 41.5 4.63 19.4 31000 6400 2 I15000805 HCV/CKD ESOPHAGIAL CANDIDIASIS,URINE CANDIDURIA CANDIDA ALBICANS
3 M 3 43 27 C 23 2.23 18.3 52000 11600 2 I15001666 OH RELATED UROSEPSIS,SEPTICIMIA E COLI+ENTROCOCCUS FECALIS,STAPH
4 F 4 56 22 C 14.5 1.16 1.1 140000 8200 3 I15001998 DCLD,CRYPTOGENIC SEPTICEMIA KLEBSIELLA
5 M 5 55 30 C 23.3 2.17 25.4 31000 4700 3 I15002673 OH,HBV SEPTICEMIA,LRTI KLEBSIELLA
6 M 6 54 21 C 31.5 3.21 14.5 130000 21000 2 I15005891 OH SBP KLEBSIELLA
7 M 7 52 23 C 19.1 1.64 2.3 148000 9000 1 I15006141 BA-ARDS SBP E COLI
8 M 8 57 24 C 20.7 1.84 2.3 171000 14700 2 I15006828 OH ASCITIC FLUID,WOUND E COLI,STREP PYOGENS
9 M 9 48 32 C 24.6 2.31 6.9 76000 16500 2 I15007780 OH,LRTI SEPTICEMIA MYROIDES SPECIES
10 F 10 69 19 C 29.7 2.98 5.6 92000 10100 1 I15003164 CRYPTOGENIC,SBP LRTI/URINE KLEBSIELLA/ECOLI
11 M 11 55 30 C 20.2 1.7 26.2 33000 14000 3 I15003880 OH,HBV SBP/LRTI/SEPTICEMIA KLEBSIELLA PNEUMONIA 
12 M 12 49 21 C 21 1.88 2.5 85000 6600 2 I15004237 OH RELATED SBP SPHINGOMONAS PAUCIMOBILLIS,ECOLI
13 M 13 46 32 C 37.1 3.98 12.1 72000 7400 2 I15010540 OH RELATED URINE E COLI
14 M 14 65 16 C 20 1.3 11 407000 10700 2 I15010549 OH UROSEPSIS ENTROCOCCUS
15 M 15 43 20 C 32 3.22 14.3 51000 10900 1 I15011287 OH SBP/SEPTICEMIA ECOLI
16 M 16 45 32  C 33 3.29 17.1 151000 15200 3 I15012886 WILLSONS THROAT/URINE
KLEBSIELLA PNEUMONIA /STREPTOCOCUS 
SALIVARIOUS
17 M 17 52 48 C 31.9 3.13 26.3 121000 28200 3 I15014210 SBP,SEPTIC SHOCK URINE CANDIDA ALBICANS
18 M 18 57  C 28.34 2.69 7.4 72000 9300 2 I15014824 DCLD,DM,CVA SEPTICEMIA/HAP
STREPTOCOCCUS AGALACTIAE/KLEBSILLA 
PNEUMONIA
19 M 19 55 24 C 29.6 2.84 21 73000 12500 2 I15014613 DM SEPTICEMIA STAPHYLOCOCCUS SPECIES
20 F 20 60 26 C 19.7 1.77 3.3 99000 17300 2 I15016097 NAFLD/AKI URINE STAPHYLOCOCCUS AUREUS
21 M 21 66 52 C 54 6.23 22.2 8000 25000 1 I15017439 CRYPTOGENIC,SBP URINE/SEPTICEMIA ECOLI/KLEBSIELLA
22 M 22 43 19 C 16.1 1.31 4 117000 10800 2 I15017587 OH/AKI URINE ENTROCOCCUS FAECELIUM
23 M 23 66 29 C 21 1.88 3.9 44000 10100 2 I15017979 NAFLD/DM URINE/LRTI CANDIDA ALBICANS/KLEBSIELLA PNEUMONIA
24 M 24 38 43 C 26.5 2.67 14.2 29000 24900 2 I15018031 OH/SBP SEPTICEMIA STAPHYLOCOCCUS SPECIES
25 M 25 60 27 C 27.6 2.6 4.6 32000 10400 3 I15018122 DLCD/HCV SPUTUM/BLOOD
KLEBSILLA PNEUMONIA/STREPTOCOOCCUS 
PYOGENS
S.No sex Sl.No age meld child PT INR BILLIRUBIN PALTELET TC HE GRADE IP NO DCLD & INFECTION ORGANISM
26 M 26 69 26 C 22.7 2.03 5.6 20000 4200 2 I15019367 NAFLD/AKI UROSEPSIS ECOLI
27 M 27 36 24 C 21 1.79 11.3 56000 13000 2 I15021451 OH SBP ASCITIC FLUID ECOLI
28 F 28 75 16 C 20.4 1.77 2.8 80000 1500 1 I15022342 HCV UROSEPSIS ECOLI
29 M 29 54 28 C 24 2.28 6.1 46000 11000 1 I15025147 OH SBP ASCITIC FLUID ECOLI
30 M 30 59 20 C 19.2 1.65 4.6 87000 10200 2 I15025446 OH SBP ASCITIC FLUID/URINE STAPHYLOCOCCUS (CONS)
31 F 31 42 13 B 13.2 1.02 2.9 156000 25100 1 I15025561 CRYPTOGENIC/LRTI LRTI KLEBSIELLA PNEUMONIA
32 M 32 42 23 C 23.5 2.15 20.7 40000 10100 2 i15026657 DCLD/UGI BLEED UTI,SEPTICEMIA
ENTEROCOCCUS FECALIS/STAPHYLOCOOCUS 
AERUGINOSA
33 M 33 43 41 C 21.2 2.88 37.3 96000 22000 2 I15025913 DCLD/SBP ASCITIC FLUID E.COLI
34 M 34 54 40 C 28.4 2.74 18.2 69000 17800 3 I15027449 DCLD/SBP UTI,BLOOD
E.COLI,ENTEROCOCCUS FECALIS, 
STAPHYLOCOCCUS AUREUS
35 M 35 44 27 C 150 23 2.8 109000 52000 3 I15028204 DCLD/AKI BLOOD STAPHYLOCOCCUS AUREUS(MSSA)
36 M 36 76 27 B 17.3 1.45 1.4 25000 3800 1 I15029529 DCLD/RUGHT LOWER LIMB CELLULITIS/AKI ASCITIC FLUID,WOUND,BLOOD S.PYOGENES/S.AUREUS/E.FECALIS
37 M 37 57 11 C 15.9 1.3 5.5 515000 22000 2 I15028856 DCLD,RIGHT LOWER LIMB DIABETIC FOOT, SEPSIS SPUTUM/BLOOD/WOUND CANDIDA SPECIES/E.COLI
38 M 38 51 9 B 15.1 1.21 7.6 484000 19500 1 I15029156 DCLD/PERIANAL ABSCESS BLOOD PSEUDOMONAS AERUGINOSA
39 M 39 42 28 C 22 2.05 13.8 59000 28200 3 I15029625 DCLA/CULTURE+ SBP ASCITIC FLUID/URINE KLEBSIELLA PNEUMONIA
40 M 40 46 29 C 19.6 1.69 3.7 124000 9100 2 I15029480 DCLD/AKI SEPTICIMIA/URINE
E.COLI/ENTEROCOCCUS FAECIUM/CANDIDA 
SPECIES
41 M 41 47 24 C 25.1 2.3 2.3 69000 12600 2 I15031397 DCLD/SBP BLOOD/URINE K.PNEUMONIAE
42 M 42 55 28 C 32.3 3.35 11 126000 12500 2 I15031670 DCLD/SBP ASCITIC FLUID/UTI MYROIDES SPECIES/E.COLI
43 M 43 46 37 C 46.6 13 12.4 43000 5600 2 I15031551 DCLD/LRTI/RIGHT LOWER LIMB CELLULITIS URINE/LRTI KLEBSIELLA/CANDIDA SPECIES
44 M 44 67 11 C 19.8 1.72 3.1 86000 6200 3 I15034156 DCLD/RIGHT LOWER LIMB CELLULITIS/ UTI URINE /WOUND K.PNEUMONIAE/E.COLI/E.FAECIUM
45 M 45 35 25 C 22.1 1.97 6.7 107000 18600 2 I15036405 DCLD UROSEPSIS/SEPTICEMIA/WOUND E.COLI/PSUDOMONAS AERUGINOSA
46 M 46 42 27 C 22.6 2.04 10.2 185000 15500 2 I15033297 DCLD-OH/AKI UROSEPSIS E.COLI/E.FAECIUM/CANDIDA
47 M 47 58 27 C 22.23 2.24 8.7 120000 9300 1 I15036122 DCLD-HBV/SBP ASCITIC FLUID KLEBSIELLA SPECIES
48 M 48 40 24 C 23.4 2.13 6.4 111000 7200 2 I15035008 DCLD-OH/SBP ASCITIC FLUID E.COLI
49 M 49 46 25 C 18.2 1.54 2.9 228000 15100 2 I15038115 DCLD-OH SEPTICEMIA E.COLI
50 M 50 45 31 C 26.8 2.54 6.8 48000 12500 3 I15035972 DCLD-OH/LRTI TRACHEAL ASPIRATE STAPH. AUREUS
